Detailed analysis of why ponatinib is not recommended for some patients

Ponatinib (Ponatinib) is a third-generation tyrosine kinase inhibitor (TKI), mainly used to treat chronic myelogenous leukemia (CML) and Philadelphiachromosome-positive acute lymphoblastic leukemia (Ph+ ALL), especially for patients harboring T315I mutations who are resistant or intolerant to other TKI patients. However, the use of ponatinib is not recommended for some patients. The main reason is closely related to its potential serious adverse reactions and individualized risk assessment.

Ponatinib has a higher risk of vascular events, including arterial thrombosis, myocardial infarction, stroke, and peripheral vascular disease. These cardiovascular risks are particularly significant in patients with a history of hypertension, diabetes, hyperlipidemia, or coronary heart disease. Therefore, for patients with high cardiovascular risk, the use of ponatinib may increase the probability of serious adverse events, thereby limiting its clinical application.

Ponatinib may cause severe toxic reactions such as liver function abnormalities, pancreatitis, and bleeding tendencies. Patients with abnormal liver function may have obstacles in drug metabolism, which increases blood drug concentration and toxicity risks; at the same time, the risk of bleeding is higher in patients with a history of previous bleeding or combined with anticoagulant drugs. In these patients, use of ponatinib may result in unpredictable serious adverse events and should be used with caution or avoidance.

Some patients have poor tolerance to ponatinib and may experience severe bone marrow suppression, rash, diarrhea and other adverse reactions, affecting their quality of life and treatment compliance. For elderly patients or people with multiple underlying diseases, these side effects may aggravate the original condition. Therefore, clinically, it is necessary to comprehensively evaluate the patient's condition, previous medication history, cardiovascular and liver and kidney function status, and make an individualized decision on whether to use ponatinib to ensure that the efficacy is maximized while reducing potential risks.

Reference link:https://www.drugs.com